北京若生智能科技有限公司
Drug Database
ME

meningococcal AC/Haemophilus influenzae B type vaccine (Hi Becam / HibACon)

✓ Approved

Chongqing Zhifei Biological · 疫苗 · 疫苗

什么是 meningococcal AC/Haemophilus influenzae B type vaccine？

meningococcal AC/Haemophilus influenzae B type vaccine 是一种疫苗，由Chongqing Zhifei Biological研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名Hi Becam, HibACon
公司Chongqing Zhifei Biological
药物类别疫苗
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved
来源： ClinicalTrials.gov, Chongqing Zhifei Biological

治疗适应症

meningococcal AC/Haemophilus influenzae B type vaccine 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsMeningococcal bacteraemia✓ Approved

相关研究文献

PubMedNature communications2026-09-11

Single-component self-assembling protein nanoparticles displaying stabilized prefusion-closed hemagglutinin trimers for influenza vaccine development.

Zhang Yi-Nan YN, Zhu Xueyong X, Braz Gomes Keegan K, Lee Yi-Zong YZ et al.

Current influenza vaccines primarily target hemagglutinin (HA), the major viral surface glycoprotein and principal determinant of neutralizing antibody (NAb) responses. However, antigenic drift and shift, together with HA's intrinsic metastability and low-pH sensitivity, limit broad and durable vaccine protection. Here, we stabilize HA in its prefusion-closed conformation through structure-guided amino acid substitutions. Targeting a conserved residue in the HA2 central triple helix-N95 in influenza A and Q95 in influenza B-provides a core design principle for modulating HA metastability across influenza A subtypes and both influenza B lineages, although the effects vary across viral groups. Using H1 CA09 and H3 HK68 as representative strains, we display stabilized HA trimers on 24-mer ferritin and 60-mer multilayered single-component self-assembling protein nanoparticles (SApNPs). In mice, HA-presenting SApNPs exhibit prolonged retention in lymph node follicles and elicit more robust germinal center responses compared with soluble trimers. Stabilized HA trimers and SApNPs induce functional antibody responses and confer varying levels of protection against homologous, heterologous, and cross-lineage viral challenges. Glycan modification enhances NAb induction or protection in some settings. Together, these findings provide mechanistic insights into HA metastability and establish a rational design framework for next-generation HA-based influenza vaccines.

PMID 42722670
阅读全文 →
PubMedTherapeutic advances in vaccines and immunotherapy2026-09-11

Therapeutic melanoma vaccines: Platforms, neoantigen strategies, and emerging combination immunotherapies.

Mhanna Daniel D, Salman Bilal B, El Hakim Rawad R, Aridi Lea L et al.

Melanoma has emerged as a major focus of cancer immunotherapy research because of its highly immunogenic nature and responsiveness to immune-based treatments. Therapeutic melanoma vaccines are designed to stimulate tumor-specific immune responses through the delivery of Tumor-Associated Antigens (TAAs), Tumor-Specific Antigens (TSAs), and personalized neoantigens. This narrative review provides an overview of current melanoma vaccine strategies, including peptide-based vaccines, dendritic cell vaccines, nucleic acid-based platforms such as mRNA, DNA, and viral vector vaccines. Recent advances in vaccine engineering and tumor genomics have accelerated the development of personalized neoantigen vaccines capable of targeting mutations unique to individual tumors. In parallel, Artificial Intelligence (AI) and Machine Learning (ML) are increasingly being incorporated into neoantigen identification pipelines to improve epitope prediction and optimize vaccine design. Combination strategies involving Immune Checkpoint Inhibitors (ICIs), particularly anti-PD-1 and anti-CTLA-4 therapies, have further enhanced interest in melanoma vaccines by helping overcome tumor-induced immune suppression and augment T-cell activation. In addition to reviewing vaccine mechanisms and emerging technologies, this manuscript examines the evolving clinical trial landscape through analysis of melanoma vaccine studies registered on ClinicalTrials.gov. Although many studies have reported encouraging safety and immunogenicity findings, challenges related to tumor heterogeneity, immune evasion, biomarker selection, and manufacturing complexity continue to limit widespread clinical implementation. Ongoing advances in computational immunology, biomaterial engineering, and precision oncology are expected to further refine melanoma vaccine development and improve therapeutic efficacy. Collectively, these innovations may help establish melanoma vaccines as an increasingly important component of future personalized cancer immunotherapy strategies.

PMID 42724148
阅读全文 →
PubMedFrontiers in endocrinology2026-09-11

Effectiveness of community-based Baduanjin combined with resistance training on cardiometabolic risk factors in older adults with type 2 diabetes: a 16-week randomized controlled trial.

Liu Fengfeng F, Zhu Xiaoxiang X, Leng Haokai H, Chen Changzhou C

Baduanjin and resistance training improve metabolism and function; however, it is unclear whether their combination reduces cardiometabolic risk in older adults with type 2 diabetes mellitus (T2DM). This study aimed to determine the effects of 16-week BDJ combined with resistance training on cardiometabolic risk parameters in older adults with T2DM. An assessor-blinded, randomized controlled. A total of 123 participants were enrolled and randomly assigned to either an intervention group (IG) that received a 16-week supervised BDJ combined with resistance training exercise program (2-3 sessions/week, 60 min/session, n=60) or a control group (CG) that received traditional health education without structured exercise (n=63). Participants in the CG were instructed to maintain their usual daily activities and attend monthly health education talks. The primary outcomes were glycosylated hemoglobin (HbA1c) and fasting plasma glucose (FPG) level, body composition, and handgrip strength. The secondary endpoints were blood pressure and lipid levels. Assessments for all outcome measures were performed at baseline and at 4-month follow-up. Statistically significant group-by-time interactions were observed for weight (B = -1.30, 95% CI [-2.17, -0.44], p = 0.003), BMI (B = -0.49, 95% CI [-0.82, -0.17], p = 0.003), waist circumference (B = -1.21, 95% CI [-2.09, -0.32], p = 0.008), Left handgrip strength (B = 2.02, 95% CI [0.98, 3.05], p < 0.001), Right handgrip strength (B = 3.75, 95% CI [2.46, 5.05], p < 0.001), FPG (B = -0.81, 95% CI [-1.43, -0.20], p = 0.010), HbA1c (B = -0.39, 95% CI [-0.64,-0.14], p = 0.003). In contrast, none of the secondary outcome measures showed statistically significant differences between the two groups at the 4-month follow-up. This study provides evidence that a 16-week program combining BDJ with resistance training can be successfully implemented in a diabetes self-management group for older adults with T2DM. By improving glycemic control, muscle strength, and body composition, the intervention improved selected cardiometabolic risk markers in older adults with T2DM. http://www.chictr.org.cn, identifier ChiCTR2600123608.

PMID 42723826
阅读全文 →
PubMedFrontiers in medicine2026-09-11

Treatment and clinical outcomes among stage II-IVA nasopharyngeal carcinoma patients with undetectable pretreatment Epstein-Barr viral DNA.

Sun Ci-Ming CM, Xu Zhen Z, Li Cheng-Hao CH, Chen Jun-Xiang JX et al.

This study analyzed the efficacy of multiple combined chemotherapy modalities on the long-term survival outcomes in stage II-IVA nasopharyngeal carcinoma (NPC) patients with undetectable pretreatment Epstein-Barr viral DNA (pre-DNA). We retrospectively analyzed 2,440 patients with stage II-IVA NPC with undetectable pre-DNA. Patients received any of the following treatment modalities: intensity-modulated radiotherapy (IMRT) alone; concurrent chemoradiotherapy (CCRT); induction chemotherapy (IC) + CCRT; IC + IMRT; or CCRT + adjuvant chemotherapy (AC) at Sun Yat-sen University Cancer Center between 2009 and 2015. Propensity score matching (PSM) was performed to balance variables. Matched patients in different treatment subgroups were analyzed by comparing survival outcomes. In the PSM cohorts, no significant differences were observed in disease-free survival (DFS), overall survival (OS), distant metastasis-free survival (DMFS), or locoregional relapse-free survival (LRRFS) between patients treated with IMRT combined with multiple chemotherapy modalities and those with IMRT alone (all P > 0.05). The estimated 5-year DFS, OS, DMFS, and LRRFS rates were 85.6% vs. 87.3% (P = 0.33), 93.5% vs. 92.2% (P = 0.64), 94.4% vs. 93.7% (P = 0.96), and 92.0% vs. 94.0% (P = 0.16), respectively. Similarly, no significant differences in 5-year DFS, OS, DMFS, or LRRFS were observed across subgroups receiving IMRT with or without concurrent chemotherapy (CC), IC followed by IMRT with or without CC, or CCRT with or without IC. However, among patients receiving CCRT with or without AC, the 5-year DFS (96.0% vs. 78.3%, P = 0.004), OS (98.0% vs. 88.1%, P = 0.027), and LRRFS (97.9% vs. 87.9%, P = 0.045) rates were significantly higher in patients without AC, whereas no significant difference was observed in DMFS (96.0% vs. 86.1%, P = 0.078). No significant differences in the survival outcomes of T3-4 stage and N2-3 disease were identified. In patients with stage II-IVA NPC with undetectable pre-treatment EBV DNA, the addition of chemotherapy to IMRT was not associated with a statistically significant improvement in survival, regardless of whether they received induction, concurrent, or adjuvant chemotherapy. Further prospective validation is required.

PMID 42723970
阅读全文 →
PubMedNature biotechnology2026-09-11

Moderna flu vaccine wins FDA approval.

PMID 42722817
阅读全文 →
PubMedFrontiers in immunology2026-09-11

Single-cell Raman profiling of B cell differentiation and leukemic transformation with transcriptome inference.

Cheng Xuelian X, Chen Ming M, Li Qing Q, Dai Linxin L et al.

Label-free profiling of cellular transcriptional and metabolic states during B cell differentiation and malignant transformation remains technically challenging. Raman spectroscopy offers a non-destructive alternative for single-cell biochemical characterization, yet its ability to infer transcriptomic profiles and distinguish leukemic cells has been limited. We established a Raman spectroscopy-based platform to profile B cell differentiation stages (HSC, pro-B, pre-B, naive B) and leukemic B-ALL cells at the single-cell level. Raman spectra were acquired from fixed cells and analyzed using principal component-linear discriminant analysis (PC-LDA) classification. An adversarial autoencoder (AAE) framework was employed to align Raman measurements with reference single-cell RNA-seq data, generating Raman-inferred transcriptomic profiles in the reference expression space. Cytochrome c expression was validated by flow cytometry, and metabolic pathways were examined via GSEA. PC-LDA resolved four B cell differentiation stages with 96.48% accuracy, identifying Raman features consistent with cytochrome c as potential spectral markers of differentiation status, validated by flow cytometry and mitochondrial membrane potential measurements. The AAE-based model generated Raman-inferred profiles that preserved major cell-type-associated transcriptomic patterns, with a mean classification accuracy of 91.78% ± 8.13% across repeated partitions. Performance varied considerably across repeated splits for pro-B (52.48-100%) and pre-B cells (34.4-100%), indicating that distinguishing closely related stages remains challenging. Applied to B-ALL, the method distinguished cord-blood-derived normal B cells from bone-marrow B-ALL cells (96.62% accuracy) and revealed reprogramming of glucose metabolism, consistent with transcriptomic enrichment analysis. This study presents a proof-of-concept framework demonstrating that Raman spectroscopy, integrated with machine learning and transcriptomic alignment, enables non-destructive, fixed-cell-based omic profiling of B cell development and leukemia. The approach bridges label-free optical readouts with transcriptome-informed profiling, opening new avenues for hematopoietic research, analysis of archived specimens, and future clinical exploration. However, these findings are based on a limited number of donors and unmatched tissue sources, and require validation in larger cohorts before clinical translation.

PMID 42723953
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多meningococcal AC/Haemophilus influenzae B type vaccine